AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33462883 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (1200 mg) plus pemetrexed (500 mg/m2) and cisplatin (75 mg/m2) or carboplatin (AUC 6 mg/mL/min)
Number of subjects: 101
Study 33462883 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (PP arm)
Number of subjects: 101
Study 33462883 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus pemetrexed and platinum-based chemotherapy
Number of subjects: 101
Study 34728531 — intervention group
Group type: EXPERIMENTAL
Intervention: sitagliptin/metformin, insulin glargine and lifestyle therapy
Number of subjects: 102
Study 34728531 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 102
Study 32275198 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention involving mindfulness-based practices and empathic collaboration activities
Number of subjects: 0
Study 32275198 — intervention group
Group type: COMPARATOR
Intervention: Waitlist group (control)
Number of subjects: 0
Study 32102812 — intervention group
Group type: EXPERIMENTAL
Intervention: QualDash quality dashboard
Number of subjects: 5
Study 36188531 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-sedation (L-Group) with bispectral index values kept in the range of 50–59
Number of subjects: 126
Study 36188531 — intervention group
Group type: COMPARATOR
Intervention: Deep-sedation (D-Group) with bispectral index values maintained in the range of 40–49
Number of subjects: 126
Study 36188531 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-sedation (L-Group)
Number of subjects: 126
Study 36315507 — intervention group
Group type: EXPERIMENTAL
Intervention: Written information in patients' own language
Number of subjects: 747
Study 36315507 — intervention group
Group type: COMPARATOR
Intervention: Verbal information
Number of subjects: 747
Study 32354052 — intervention group
Group type: EXPERIMENTAL
Intervention: ICT-based health management services including respiratory and urinary care devices and home visit occupational therapy
Number of subjects: 8
Study 35131729 — intervention group
Group type: EXPERIMENTAL
Intervention: Superovulation with letrozole, clomiphene, or gonadotropins
Number of subjects: 173
Study 32773651 — intervention group
Group type: EXPERIMENTAL
Intervention: 4200 IU/week vitamin D
Number of subjects: 1257
Study 32773651 — intervention group
Group type: EXPERIMENTAL
Intervention: 16800 IU/week vitamin D
Number of subjects: 1257
Study 32773651 — intervention group
Group type: EXPERIMENTAL
Intervention: 28000 IU/week vitamin D
Number of subjects: 1257
Study 32773651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1257
Study 33011721 — intervention group
Group type: EXPERIMENTAL
Intervention: Pillcam SB3
Number of subjects: 44
Study 33011721 — intervention group
Group type: COMPARATOR
Intervention: OMOM CE
Number of subjects: 44
Study 33219007 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi (TC)
Number of subjects: 92
Study 33219007 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi (TC) with maintenance classes
Number of subjects: 92
Study 35466907 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful parenting intervention
Number of subjects: 7
Study 34711333 — intervention group
Group type: EXPERIMENTAL
Intervention: MAP ≥75 mm Hg
Number of subjects: 458
Study 34711333 — intervention group
Group type: COMPARATOR
Intervention: Control (MAP ≥60 mm Hg)
Number of subjects: 458
Study 34608532 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - PAT summary provided to patient treating team
Number of subjects: 122
Study 34608532 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - No PAT summary provided to treating team
Number of subjects: 122
Study 34608532 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup of families in Targeted risk level at T1
Number of subjects: 122
Study 34608532 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup of families with Universal risk at T1
Number of subjects: 122
Study 34608532 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall psychosocial risk levels
Number of subjects: 122
Study 34060300 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-step self-etch adhesive (O-XTR)
Number of subjects: 50
Study 34060300 — intervention group
Group type: COMPARATOR
Intervention: 3-step etch & rinse adhesive (O-FL)
Number of subjects: 50
Study 32784794 — intervention group
Group type: EXPERIMENTAL
Intervention: MOD-INT (60% VO2peak, intermittent exercise)
Number of subjects: 12
Study 32784794 — intervention group
Group type: COMPARATOR
Intervention: MOD-CON (60% VO2peak, continuous exercise)
Number of subjects: 12
Study 32784794 — intervention group
Group type: COMPARATOR
Intervention: LOW-CON (40% VO2peak, continuous exercise)
Number of subjects: 12
Study 32784794 — intervention group
Group type: EXPERIMENTAL
Intervention: LOW-INT (40% VO2peak, intermittent exercise)
Number of subjects: 12
Study 616864714 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin-bound paclitaxel (260 mg/m²) combined with pirarubicin (75 mg/m²)
Number of subjects: 62
Study 616864714 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel (175 mg/m²) combined with pirarubicin (75 mg/m²)
Number of subjects: 62
Study 35614875 — intervention group
Group type: EXPERIMENTAL
Intervention: P2X3-receptor antagonist gefapixant
Number of subjects: 0
Study 33823163 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS, applied to the primary occipital cortex (Oz) for 20 min at 1.5 mA intensity
Number of subjects: 50
Study 33823163 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS, applied to the primary occipital cortex (Oz) for 20 min at 1.5 mA intensity
Number of subjects: 50
Study 33823163 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation, applied to the middle of the head (Cz) for 20 min
Number of subjects: 50
Study 34617561 — intervention group
Group type: EXPERIMENTAL
Intervention: FODMAPs (50 g/d)
Number of subjects: 103
Study 34617561 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten (17.3 g/d)
Number of subjects: 103
Study 34617561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 34391566 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting cabotegravir plus rilpivirine
Number of subjects: 0
Study 34518276 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO-symptom monitoring using a web application with active and reactive alert approaches.
Number of subjects: 584
Study 34518276 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO-symptom monitoring using a web application.
Number of subjects: 584
Study 34518276 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PRO-symptom monitoring).
Number of subjects: 584
Study 32215653 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat grafting
Number of subjects: 10
Study 32215653 — intervention group
Group type: COMPARATOR
Intervention: Control (intact side of abdomen)
Number of subjects: 10
Study 35576072 — intervention group
Group type: EXPERIMENTAL
Intervention: SMR–Beta1 neurofeedback training (12–18 Hz) for 10 sessions (3 days a week)
Number of subjects: 24
Study 35576072 — intervention group
Group type: COMPARATOR
Intervention: Control group (without any NFB training)
Number of subjects: 24
Study 34616618 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g of copra meal hydrolysate (CMH)
Number of subjects: 60
Study 34616618 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g of copra meal hydrolysate (CMH)
Number of subjects: 60
Study 34616618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 34196787 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute Resistance Exercise (RE)
Number of subjects: 6
Study 34196787 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute Aerobic Exercise (AE)
Number of subjects: 6
Study 34196787 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute Aerobic Exercise (AE) and Acute Resistance Exercise (RE)
Number of subjects: 6
Study 32591170 — intervention group
Group type: EXPERIMENTAL
Intervention: neuroplasticity based computerized cognitive remediation (nCCR) for 30 hours over 4 weeks
Number of subjects: 0
Study 32591170 — intervention group
Group type: EXPERIMENTAL
Intervention: neuroplasticity based computerized cognitive remediation (nCCR)
Number of subjects: 0
Study 32591170 — intervention group
Group type: COMPARATOR
Intervention: active control condition
Number of subjects: 0
Study 34172486 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom sensitisation session delivered by a lay counsellor (IC)
Number of subjects: 835
Study 34172486 — intervention group
Group type: COMPARATOR
Intervention: Whole-school sensitisation (teacher-meetings and whole-school activities) (CC)
Number of subjects: 835
Study 35925755 — intervention group
Group type: EXPERIMENTAL
Intervention: Ada app-based diagnostic tool
Number of subjects: 450
Study 35925755 — intervention group
Group type: COMPARATOR
Intervention: Classic doctor-patient interaction
Number of subjects: 450
Study 35925755 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined diagnostic accuracy of Ada and ER physician
Number of subjects: 450
Study 35925755 — intervention group
Group type: EXPERIMENTAL
Intervention: Early diagnosis and rapid treatment allocation
Number of subjects: 450
Study 34197486 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise intervention (12-week progressive multi-component programme)
Number of subjects: 35
Study 34197486 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 35
Study 34197486 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise intervention
Number of subjects: 35
Study 33463655 — intervention group
Group type: EXPERIMENTAL
Intervention: Centesys model
Number of subjects: 20
Study 33463655 — intervention group
Group type: COMPARATOR
Intervention: agar-based model
Number of subjects: 20
Study 35413774 — intervention group
Group type: EXPERIMENTAL
Intervention: Red-fleshed apple (RFA)
Number of subjects: 121
Study 35413774 — intervention group
Group type: EXPERIMENTAL
Intervention: ACN-rich infusion from aronia fruit (ARO)
Number of subjects: 121
Study 33464924 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined double‐bundle ACLR and ALSA (ALSA group)
Number of subjects: 16
Study 33464924 — intervention group
Group type: COMPARATOR
Intervention: Isolated double‐bundle ACLR (ACLR group)
Number of subjects: 16
Study 35941264 — intervention group
Group type: EXPERIMENTAL
Intervention: FGF‐2‐CP composite layer‐coated screws subjected to gamma‐ray sterilization at 25 kGy (GS group)
Number of subjects: 2
Study 35941264 — intervention group
Group type: COMPARATOR
Intervention: FGF‐2‐CP composite layer‐coated screws subjected to aseptic storage (AS group)
Number of subjects: 2
Study 33228756 — intervention group
Group type: EXPERIMENTAL
Intervention: RFA/PVA and EBRT
Number of subjects: 0
Study 33228756 — intervention group
Group type: COMPARATOR
Intervention: EBRT alone
Number of subjects: 0
Study 33829274 — intervention group
Group type: EXPERIMENTAL
Intervention: self-hypnosis/self-care
Number of subjects: 575
Study 33829274 — intervention group
Group type: EXPERIMENTAL
Intervention: music/self-care
Number of subjects: 575
Study 33829274 — intervention group
Group type: EXPERIMENTAL
Intervention: self-care
Number of subjects: 575
Study 33829274 — intervention group
Group type: EXPERIMENTAL
Intervention: psychoeducation/cognitive behavioural therapy
Number of subjects: 575
Study 33829274 — intervention group
Group type: COMPARATOR
Intervention: randomized treatment
Number of subjects: 575
Study 33829274 — intervention group
Group type: COMPARATOR
Intervention: waiting more than 4 months before starting treatment
Number of subjects: 575
Study 33829274 — intervention group
Group type: EXPERIMENTAL
Intervention: intermediate or high educational level
Number of subjects: 575
Study 34782961 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg)
Number of subjects: 50
Study 34782961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 32247522 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineural administration of 40‐mg ketamine plus 0.375% ropivacaine in 40‐mL volume (Group RNK)
Number of subjects: 76
Study 32247522 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mL of 0.375% ropivacaine plus IV ketamine 40 mg (Group RIK)
Number of subjects: 76
Study 32247522 — intervention group
Group type: COMPARATOR
Intervention: 40 mL of 0.375% ropivacaine (Group R)
Number of subjects: 76
Study 36173235 — intervention group
Group type: EXPERIMENTAL
Intervention: BP with fast-acting insulin aspart (BP-F), N=114
Number of subjects: 275
Study 36173235 — intervention group
Group type: COMPARATOR
Intervention: BP with standard care insulin delivery (SC), N=54
Number of subjects: 275
Study 36173235 — intervention group
Group type: EXPERIMENTAL
Intervention: BP with aspart or lispro (BP-A/L), N=107
Number of subjects: 275
Study 33792623 — intervention group
Group type: EXPERIMENTAL
Intervention: Tislelizumab (200 mg, day 1) plus paclitaxel (175 mg/m2, day 1) and carboplatin (area under the concentration of 5, day 1)
Number of subjects: 355
Study 33792623 — intervention group
Group type: EXPERIMENTAL
Intervention: Tislelizumab plus nab-paclitaxel (100 mg/m2, days 1, 8, and 15) and carboplatin
Number of subjects: 355
Study 33792623 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel and carboplatin
Number of subjects: 355
Study 32075406 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab 30 mg
Number of subjects: 888
Study 32075406 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab 100 mg
Number of subjects: 888
Study 32075406 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab 300 mg
Number of subjects: 888
Study 32075406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 888
Study 34490801 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast cancer patients with perception about Vitamin D deficiency
Number of subjects: 402
Study 34490801 — intervention group
Group type: COMPARATOR
Intervention: Control group (randomly selected females) with perception about Vitamin D deficiency
Number of subjects: 402
Study 34490801 — intervention group
Group type: EXPERIMENTAL
Intervention: Women aged 41 to 50 years
Number of subjects: 402
Study 34490801 — intervention group
Group type: EXPERIMENTAL
Intervention: Urban women
Number of subjects: 402
Study 34175638 — intervention group
Group type: EXPERIMENTAL
Intervention: SAPB with 30 ml of 0.5% ropivacaine
Number of subjects: 198
Study 34175638 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline (Control group)
Number of subjects: 198
Study 36436481 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast 10 mg BD for 10 days plus standard care
Number of subjects: 40
Study 36436481 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus standard care
Number of subjects: 40
Study 33221027 — intervention group
Group type: COMPARATOR
Intervention: Silexan 80 mg
Number of subjects: 75
Study 33221027 — intervention group
Group type: COMPARATOR
Intervention: Silexan 80 mg/d (multiple dosing for 7 days)
Number of subjects: 75
Study 33221027 — intervention group
Group type: EXPERIMENTAL
Intervention: Silexan 160 mg
Number of subjects: 75
Study 33221027 — intervention group
Group type: EXPERIMENTAL
Intervention: Silexan 320 mg
Number of subjects: 75
Study 33221027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 33221027 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 1 mg
Number of subjects: 75
Study 32245512 — intervention group
Group type: EXPERIMENTAL
Intervention: Music listening for a minimum of 30 minutes at bedtime for 4 weeks
Number of subjects: 0
Study 32245512 — intervention group
Group type: COMPARATOR
Intervention: Standard care control group
Number of subjects: 0
Study 36163686 — intervention group
Group type: EXPERIMENTAL
Intervention: active intermittent theta burst stimulation (iTBS)
Number of subjects: 81
Study 36163686 — intervention group
Group type: COMPARATOR
Intervention: sham intermittent theta burst stimulation (iTBS)
Number of subjects: 81
Study 33980763 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 2723
Study 33980763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2723
Study 32729843 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring program
Number of subjects: 122
Study 32729843 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote monitoring program
Number of subjects: 122
Study 32729843 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 122
Study 36445905 — intervention group
Group type: EXPERIMENTAL
Intervention: CPI monitor turned on (intervention arm)
Number of subjects: 525
Study 36445905 — intervention group
Group type: COMPARATOR
Intervention: CPI monitor turned off (control arm)
Number of subjects: 525
Study 35340950 — intervention group
Group type: EXPERIMENTAL
Intervention: King Vision videolaryngoscope
Number of subjects: 100
Study 35340950 — intervention group
Group type: COMPARATOR
Intervention: CMAC D blade videolaryngoscope
Number of subjects: 100
Study 36028073 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIE-D (Two sessions of high-intensity interval exercise separated by 3 hours)
Number of subjects: 20
Study 33591469 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg intravenous ZOL every 3 weeks for 1 year (17 total doses)
Number of subjects: 120
Study 33591469 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 120
Study 35359478 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral nasociliary and maxillary nerve blocks with 12 mL of equal volumes of 0.5% bupivacaine and 2% lignocaine after induction of general anaesthesia
Number of subjects: 51
Study 35359478 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral nasociliary and maxillary nerve blocks
Number of subjects: 51
Study 35359478 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nerve block)
Number of subjects: 51
Study 33217697 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading rate of 8.3 kN/s at 0.5 Hz
Number of subjects: 32
Study 33217697 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading rate of 4.2 kN/s at 0.5 Hz
Number of subjects: 32
Study 33217697 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading rate of 8.3 kN/s at 1 Hz
Number of subjects: 32
Study 33217697 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading rate of 4.2 kN/s at 1 Hz
Number of subjects: 32
Study 36263451 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily emollient plus standard skin‐care advice
Number of subjects: 1394
Study 36263451 — intervention group
Group type: COMPARATOR
Intervention: Standard skin‐care advice alone
Number of subjects: 1394
Study 33880760 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg orally alone
Number of subjects: 10
Study 33880760 — intervention group
Group type: COMPARATOR
Intervention: Rifampin 600 mg i.v. infusion
Number of subjects: 10
Study 32290859 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-Focused Emotion-Regulation Therapy (GET)
Number of subjects: 0
Study 32290859 — intervention group
Group type: COMPARATOR
Intervention: Individual Supportive Therapy (ISP)
Number of subjects: 0
Study 32087762 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-pressure group (7 mm Hg)
Number of subjects: 138
Study 32087762 — intervention group
Group type: COMPARATOR
Intervention: Standard-pressure group (12 mm Hg)
Number of subjects: 138
Study 36107179 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy
Number of subjects: 154
Study 36107179 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy + homeopathic protocol
Number of subjects: 154
Study 36107179 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic protocol
Number of subjects: 154
Study 34941168 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided quadratus lumborum block (QLB) with 20 mL of 0.25% ropivacaine on each side
Number of subjects: 62
Study 34941168 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (control)
Number of subjects: 62
Study 32111521 — intervention group
Group type: EXPERIMENTAL
Intervention: Brazil nut supplementation (one unit daily for 3 months)
Number of subjects: 32
Study 34774185 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG (2 g/kg over 4 days)
Number of subjects: 146
Study 34774185 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sodium chloride 0.9% equivalent volume over the same period)
Number of subjects: 146
Study 34774185 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG
Number of subjects: 146
Study 34774185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 33256887 — intervention group
Group type: EXPERIMENTAL
Intervention: Blog written by a registered dietitian (RD)
Number of subjects: 26
Study 33167114 — intervention group
Group type: EXPERIMENTAL
Intervention: CT coronary angiography (CTA)
Number of subjects: 102
Study 33167114 — intervention group
Group type: COMPARATOR
Intervention: Control group (elective ICA examination)
Number of subjects: 102
Study 33217092 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor (SGLT2i)
Number of subjects: 119
Study 33217092 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazolidinedione (TZD)
Number of subjects: 119
Study 33686037 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lignocaine with 1:50,000 epinephrine
Number of subjects: 120
Study 33686037 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine
Number of subjects: 120
Study 36120142 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultural and creative product design in sports events
Number of subjects: 620
Study 36120142 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 620
Study 33685306 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoid (GC) injection
Number of subjects: 44
Study 33685306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 32641747 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin
Number of subjects: 1864
Study 32641747 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1864
Study 34216500 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app for capturing supplemental health information during pregnancy
Number of subjects: 64
Study 34429410 — intervention group
Group type: EXPERIMENTAL
Intervention: Genome sequencing (GS)
Number of subjects: 200
Study 34429410 — intervention group
Group type: COMPARATOR
Intervention: Control (family histories of disease review only)
Number of subjects: 200
Study 32969999 — intervention group
Group type: EXPERIMENTAL
Intervention: Jackknife position
Number of subjects: 10
Study 34628232 — intervention group
Group type: EXPERIMENTAL
Intervention: Blind weighing
Number of subjects: 53